Skinvisible Granted US Sunscreen Patent for UVA Absorber
Broad Spectrum UVA / UVB Sunscreens with Invisicare Offer Eight Hours of Photostability
LAS VEGAS, Nevada. March 7, 2012 - Skinvisible, Inc. (SKVI: OTCQB), a developer of topical and transdermal formulations using its patented Invisicare technology, announced today that it has been granted a new patent from the United States Patent and Trademark Office for "Sunscreen Composition With Enhanced UVA Absorber Stability and Methods", Patent Number 8128913. This patent further strengthens the company's existing intellectual property assets. The patent provides protection for its sunscreen formulation in the United States until November 2029.
Skinvisible has developed three sunscreen formulations using avobenzone; SPF 15, 30 and 50. Although avobenzone is recognized as the best sun absorber in the US providing UVA protection, it is known to degrade in sunlight in less than two hours, resulting in less skin protection over time. Skinvisible's new formulation with avobenzone has eight hours of photostability, a unique advantage for everyone who uses sunscreens and works or plays outdoors. The essential benefits of Skinvisible's sunscreen formulations are derived from its patented Invisicare polymer delivery system. This patent adds a distinctive new category of Invisicare to Skinvisible's portfolio, one which adds the benefit of photostability to sunscreen formulations and other future developments.
While the SPF of a sunscreen only provides the level of UVB protection, a sunscreen with UVA protection protects the skin from ultraviolet rays that penetrate deeper, go through glass and clouds and can cause more severe skin damage, wrinkling and even skin cancer. The FDA has ruled that only sunscreens with a critical wavelength above 370 nm are allowed to claim they provide UVA protection. Skinvisible's avobenzone sunscreens surpass this criterion allowing Skinvisible's sunscreens to meet the new FDA's 2012 guidelines and therefore can be labeled as having "broad spectrum" UV protection.
"With global sales in suncare reaching $1.7 billion in 2010 and North America accounting for 21% of that market, the value of this patented asset is tremendous," stated Mr. Terry Howlett, President and CEO, Skinvisible. "This patent maximizes the earning potential of our sunscreen formulations giving them an increased value when licensed. Skinvisible persists in securing a licensing agreement for its sunscreen formulations with the objective of maximizing revenue generation and continuing our mission of creating value for our company and its shareholders."